FDA Approves Donidalorsen as First RNA-Targeted Therapy to Prevent Hereditary Angioedema Attacks

The U.S. Food and Drug Administration (FDA) has granted approval for donidalorsen, marking it as the first RNA-targeted therapy designed to prevent hereditary angioedema (HAE) attacks. This development introduces a new treatment option that significantly reduces the frequency of HAE episodes while offering a more convenient administration method compared to existing therapies.

Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of severe swelling in various parts of the body, including the extremities, gastrointestinal tract, and airways. Donidalorsen works by targeting RNA to address the underlying causes of these attacks. Clinical trials demonstrated that the therapy effectively reduced attack rates in patients with HAE. Additionally, its administration process is designed to be user-friendly, potentially improving adherence among individuals managing this chronic condition.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: August 21, 2025

Author

Mark Chiang